Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Tislelizumab with Fruquintinib, Metronidazole

"Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle."

Trial Locations (2)

Unknown

RECRUITING

Shanghai First People's Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Ninth People's Hospital, Shanghai

All Listed Sponsors
lead

Jing-yuan Fang, MD, Ph. D

OTHER